Establishment of a reference interval for high-sensitivity cardiac troponin I in healthy adults from the Sichuan area

Shunjun Li, MD*, Yue Zuo, MD, Wenfang Huang, MD

Abstract
High-sensitivity cardiac troponin I (hs-cTnl) has been used in the diagnosis and risk stratification of acute myocardial infarction. However, there is no common consensus on an hs-cTnl reference interval for the Chinese population. The aim of this study was to describe the distribution of hs-Tnl and establish the 99th percentile reference interval for hs-cTnl in healthy adults from the Sichuan area.

Serum specimens were collected from 1485 healthy adults (731 men and 754 women ranging in age from 18 to 85 years) in Sichuan Provincial People’s Hospital. All specimens were divided into 4 groups according to age distribution: 18 to 35 years, 36 to 50 years, 51 to 65 years, and ≥66 years. Specimens were further divided into younger/middle and older-aged groups based on a cut-off age of 50 years. The serum hs-cTnl concentration was determined using the Abbott ARCHITECT STAT hs-cTnl assay.

The serum hs-cTnl concentration increased with age (P<0.05). The 99th percentiles of hsTnl were 28.0 pg/mL among the whole population, 31.1 pg/mL among men, and 22.7 pg/mL among women. The age-dependent 99th percentiles of hs-cTnl in men and women were as follows: 28.8 versus 12.5 pg/mL for 18 to 35 years, 20.4 versus 9.2 pg/mL for 36 to 50 years, 24.2 versus 13.6 pg/mL for 51 to 65 years, and 27.9 versus 32.2 pg/mL for ≥66 years.

The 99th percentile reference interval for hs-cTnl in healthy adults from the Sichuan area was similar to the manufacturer’s recommendation. Men had a higher 99th percentile hs-cTnl value than women in the age range of 18 to 65 years.

Abbreviations: AMI = acute myocardial infarction, hs-cTnl = high-sensitivity cardiac troponin I, URL = upper reference limit.

Keywords: cardiac troponin I, health checkup, healthy individuals, high-sensitivity, reference interval

1. Introduction
Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Cardiac troponins are proteins of the contractile apparatus in the heart muscle and are classified as: troponin I, troponin T, and troponin C based on their function. As cardiac troponins are essential components of the contractile apparatus of myocytes, elevation of circulating cardiac troponins concentration reflects injury of the myocardial cells. Cardiac troponins I and T have been identified as the primary biomarkers for the early diagnosis of acute myocardial infarction (AMI) and for risk stratification of patients suspected of having acute coronary syndrome.[1] Cardiac troponin I is a highly specific indicator of myocyte injury. Therefore, measurement of cardiac troponin I is considered to be highly specific for myocardial injury. International guidelines recommend one concentration measurement of cardiac troponins above the 99th percentile for a healthy reference population with a coefficient of variation of 10% as the cut-off value for the diagnosis of AMI.[2] However, 1st-generation troponins assays were not recommended for the biomarkers of choice in the early diagnosis of AMI due to lack of the recommended detection limit and precision.

Cardiac troponins assays can be classified as low, medium, high, and ultrasensitive according to their sensitivity.[3] In order to detect the minimal release of troponins, a new generation of high-sensitivity troponins assay has already been introduced into clinical practice.[4] High-sensitivity troponins assays can measure troponins concentrations above the limit of detection in ≥50% of healthy individuals, with a ≤10% coefficient of variation at the 99th percentile.[5] As the sensitivity of troponins assays has improved, these new generation assays can detect the minimal release of cardiac troponins below the 99th percentile, which was often undetectable with the conventional troponins assays. The high-sensitivity cardiac troponin I (hs-cTnl) assay is characterized by a detection limit of concentration in the range of picograms of protein per millilitre.[6] Despite the recommended diagnostic cut-off concentrations for high-sensitivity troponin I (hsTnl), a broad range of cut-off values exist across individual laboratories. A major cause of the broad variation of the 99th percentile cut-off values for hs-cTnl is the selection criteria of the reference population.[7] Males and older persons tend to have higher troponin I values than females and younger persons.[8-11] In addition, the increasingly analytical sensitivity of new troponins assays requires validation in the 99th percentile estimation.

Editor: Bernhard Schaller.
The authors have no funding and conflicts of interest to disclose.

Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China.

* Correspondence: Shunjun Li, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, #32 1st Circle Rd Qingyang District, 610072 Chengdu, China (e-mail: jshunjun@yeah.net).

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2017) 96(14):e6252
Received: 9 November 2016 / Received in final form: 7 February 2017 / Accepted: 7 February 2017
http://dx.doi.org/10.1097/MD.0000000000006252
The normative reference interval for hs-cTnI used in China was determined for healthy Western populations. Considering ethnic diversity, the cut-off value for the 99th percentile hs-cTnI concentration for a Western population might not be applicable for the Chinese population, and ignoring this issue could result in misleading clinical decision-making. Therefore, establishment of a reference interval for hs-cTnI in healthy Chinese adults is necessary. In this study, we aimed to describe the distribution of hsTnI and establish the 99th percentile local reference interval for hs-cTnI in healthy adults from the Sichuan area.

2. Materials and methods

2.1. Study population

Between April 17 and April 26, 2015, a total of 1485 healthy adults seen for check-ups (mean age: 36 ± 13 years) comprising 731 males and 754 females were randomly selected from the Department of Medical Examination Center of Sichuan Provincial People’s Hospital. The occupations of the adults spanned government, enterprises, public institutions, schools, and service industries. Randomization was performed by selecting the odd number of the medical record sequence. The inclusion criteria used to define healthy subjects were as follows: normal body mass index 18.5 to 23, no history of cardiovascular disease; normal liver and renal functions; and without major trauma or cardiac medication history within 3 months. Pregnant women, extreme athletes, those with a chronic disorder requiring regular medication, and those with edema, pleural effusion or ascites, muscle atrophy, cardiac insufficiency, urinary obstruction, or a history of diabetes, hyperlipemia, and hypertension were excluded. Participants were categorized based on age into 4 groups: 18 to 35 years, 36 to 50 years, 51 to 65 years, and ≥ 66 years. In addition, participants were further divided into younger and older-aged groups according to the cut-off age of 50 years. The study protocol was approved by the Ethics Committee of Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital and followed the ethical principles of the Declaration of Helsinki. All participants provided written informed consent.

2.2. Specimen collection and routine clinical assessment

Three milliliters of blood were obtained from a forearm vein after at least 8 hours of fasting from all participants. After complete coagulation for 120 minutes, blood specimen was centrifuged at 10,000 × g for 10 minutes within 2 hours of collection. Serum samples were stored at −80°C in a freezer until analysis. Serum levels of total bilirubin, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, total protein, albumin, globulin, alkaline phosphatase, gamma-glutamyltransferase, urea nitrogen, creatinine, uric acid, glucose, triglyceride, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol were measured by the automated ARCHITECT c2000 (Abbott Diagnostics, Abbott Park, IL) according to standard clinical laboratory procedures. In addition, demographic characteristics, anthropometric data, heart rate, blood pressure, 12-lead electrocardiogram, chest radiography, and echocardiography were recorded.

Blood pressure was measured in the sitting position. Hypertension was defined as a systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg, or the use of antihypertensive agents. Diabetes was diagnosed as fasting blood glucose level ≥ 7 mmol/L, or the use of insulin or oral any hypoglycemic agents. Participants with a body mass index > 30 m²/kg were grouped as obese.

2.3. Determination of hs-cTnI

hs-cTnI was measured with the Abbott ARCHITECT STAT hs-cTnI assay (Abbott Diagnostics) on Abbott i2000 Automatic Immune Analyzers. Precision for the assay was assessed based on the document of the CLSI EP5-A2. Coefficients of variation at the 99th percentiles were tested with participant’s samples that had been diluted with assay diluent.

2.4. Statistical analysis

All analyses were conducted using SPSS 19.0 statistical software (SPSS Inc., Chicago, IL) and M5 Excel 2010. Categorical data are expressed as number or percentage. Normally distributed data are presented as mean ± SD. The Kolmogorov–Smirnov test was applied to verify the normal distribution of variables. The 99th percentile upper reference limit (URL) based on age and gender was calculated in accordance with the CLSI EP28-A3c guideline using a nonparametric analysis. The nonparametric Mann–Whitney U test was used to compare differences in hs-cTnI values between different groups. A P-value < 0.05 was considered as statistically significant.

3. Results

3.1. Characteristics of the study population

Figure 1 shows the flow diagram of participant enrollment. Of 4341 adults seen for health check-ups, 1210 with known chronic disease were excluded. Of 3131 possible enrollment, 101 adults refused participation. A total of 3030 participants underwent random selection by odd number of the medical record sequence. We further excluded those who presented with coronary heart disease (n = 10), hypertension (n = 7), diabetes (n = 13), hyperlipidemia (n = 5), chronic kidney disease (n = 3), and obesity (n = 2) on the basis of the study inclusion and exclusion criteria. Thus, a total of 1485 healthy adults were enrolled including 731 men (49.2%) and 754 women (50.8%). Participant age varied from 18 to 85 years (mean age, 36 ± 13 years). Among the 731 men, 310 were aged from 15 to 35 years, 226 from 36 to 50 years, 153 from 51 to 65 years, and 42 were ≥ 66 years. Of the 754 women, 323 were aged from 15 to 35 years, 252 from 36 to 50 years, 144 from 51 to 65 years, and 35 were ≥ 66 years.

3.2. Determination of the 99th percentile for hsTnI

The Kolmogorov–Smirnov test demonstrated the skewed distribution of serum hs-cTnI concentration in different age and gender groups (all P < 0.05). Figure 2 shows the scatter plot of hsTnI according to the age distribution. The range of measured serum hs-cTnI concentrations in the selected healthy participants was 0.1 to 39.13 pg/mL. As shown in Fig. 3, the 99th percentile URL hs-cTnI concentration was 28.0 pg/mL for all selected healthy adults according to the nonparametric method. The 99th percentile cut-off was significantly higher in men (31.1 pg/mL) than in women (22.7 pg/mL). The male 99 percentile URLs for hs-cTnI concentration were 28.8 pg/mL for ages 18 to 35 years, 20.4 pg/mL for 36 to 50 years, 24.2 pg/mL for 51 to 65 years, and 27.9 pg/mL for age ≥ 66 years. In women, the 99th percentile URLs for hs-cTnI concentration were 12.5 pg/mL.
for ages 18 to 35 years, 9.2 pg/mL for 36 to 50 years, 13.6 pg/mL for 51 to 65 years, and 32.2 pg/mL for age ≥ 66 years. The gender difference in the serum hs-cTnI concentration was more significant for the ages 18 to 65 years. The 99th percentiles for hs-cTnI concentration for the total study population, as well as with the age and gender differences, are summarized in Table 1.

### 3.3. Hs-cTnI distribution according to age and gender

The median values of serum hs-cTnI concentration increased with increasing age across the age groups ($P < 0.05$). Men showed a higher serum hs-cTnI concentration than women from age 18 to 65 years ($P < 0.05$). In the younger and middle-aged groups, the serum hs-cTnI concentration was significantly lower in women than in men ($P < 0.05$). By contrast, there was no significant gender difference in the serum hs-cTnI concentration in the older-aged group ($P > 0.05$). The distributions of serum hs-cTnI concentration according to age and gender are shown in Fig. 4.

### 4. Discussion

Estimated biological reference intervals are the most widely used tools in the medical decision-making process. In the current study, we estimated the age- and gender-specific 99th percentile cut-off values using the Abbott hs-cTnI assay in 1487 adults seen for health check-ups from the Sichuan area. We established 28.0 pg/mL as the 99th percentile cut-off value for hs-cTnI in the
overall study population. The male and female 99th percentile cut-off values were 31.1 and 22.7 pg/mL, respectively. Specifically, there were significant gender-related differences in the 99th percentile cut-off values for hs-cTnI, with men having a higher concentration from ages 18 to 65 years. However, there were no significant gender differences in the 99th percentile value for hs-cTnI concentration in the 66 years or older subgroup.

Cardiac troponins are blood biomarkers that reflect myocardial cell damage. Assays for cardiac troponin I and T have become widely accepted tools in the early diagnosis of AMI. With the improved sensitivity and precision, the latest troponins assays allow the measurement of hs-cTnI in healthy individuals. Different studies have reported different reference intervals even for the same hs-cTnI assay. Differences in study populations and analytical performance of the assay may largely explain the inconsistent findings of the various studies. For studies on the Abbott hs-cTnI assay in healthy individuals, the 99th percentile cut-off value has ranged from 12.3 to 27 pg/mL. Our overall 99th percentile cut-off value was greater than those reported by Apple et al. (23 pg/mL), Zeller et al. (27.0 pg/mL) and Aw et al. (25.6 pg/mL). The male 99th percentile cut-off value in our study was slightly higher than the value reported by Krintus et al. (27 pg/mL) but our female 99th percentile cut-off value was quite different (22.7 vs 11.0 pg/mL). The healthy populations enrolled in these studies were of sufficient sample size to determine reliable overall and gender-specific 99th percentile

![Figure 3. Distribution of high-sensitivity cardiac troponin I (hs-cTnI) concentration in all participants (A), women (B), and men (C). The 99th percentiles were as follows: all participants 28.0 pg/mL (n = 1485), women 22.7 pg/mL (n = 731), and men 31.1 pg/mL (n = 754).](image)

| Group       | Men          | Women       | Overall     |
|-------------|--------------|-------------|-------------|
| Group       | 99th percentile | Median | Minimum | Maximum | 99th percentile | Median | Minimum | Maximum |
| 18–35 years | 28.8 | 1.9 | 0.1 | 39.1 | 12.5 | 1.4 | 0.2 | 29.1 |
| 36–50 years | 20.4 | 2.5 | 0.5 | 29.9 | 9.2 | 1.7 | 0.3 | 18.8 |
| 51–65 years | 24.2 | 3.0 | 1.2 | 31.6 | 13.6 | 2.3 | 0.5 | 19.4 |
| ≥66 years   | 27.9 | 3.4 | 1.8 | 27.9 | 32.2 | 3.4 | 0.9 | 32.2 |
| Overall     | 26.0 | 2.5 | 0.1 | 39.1 | 18.8 | 1.7 | 0.1 | 32.2 |

*Fewer subjects in ≥66 years subgroup, 99th percentile skewed.*
values. In another Chinese study conducted in Shanghai, the Abbott 99th percentile value for hs-cTnI was 21 pg/mL for all healthy participants, which was lower than the manufacturer’s recommendation of 28 pg/mL. This discrepancy may be related to the different age distribution of the participants. Although the 99th percentile cut-off values for hs-cTnI in our study were close to the recommendations of the Western laboratory, establishing the age-, gender-, and ethnic-specific reference intervals for hs-cTnI is necessary.

In addition to gender-specific differences, we observed a higher median concentration of hs-cTnI among older individuals. Median values of serum hs-cTnI concentration increased with advancing age. Particularly, we observed a sharply increase in the 99th percentile value for hs-cTnI over 66 years in the female subgroup. This finding was supported by a multicenter study in the Italian population. Eggers et al. investigated the hs-cTnI concentrations in 814 community-dwelling individuals at both 70 and 75 years of age, and they found aging resulted in an increase in the 99th percentile for hs-cTnI value, especially in men. These findings suggest that the optimal cut-off value should be higher for adults over 70 years of age than for younger patients when applying hs-cTnI decision thresholds in clinical settings. An increased hs-cTnI concentration should not be interpreted with isolation. As the hs-cTnI concentration was relatively lower in healthy adults, physiological variation of hs-cTnI may affect the disease diagnosis and treatment. The physiological variation and coefficients of variation of hs-cTnI were 18% and 21%, respectively. The clinical implications of implementation of an hs-cTnI assay should be within the context of a patient’s medical history and presentation. Apart from at least one concentration of cardiac troponins above the 99th percentile cut-off, an increase or decrease in cardiac troponins concentration is required for the diagnosis of AMI.

The participant selection criteria had a significant impact on the 99th percentile value. However, defining the appropriate healthy population to determine the 99th percentile is challenging. For a study reporting cardiac troponins with the 99th percentile, at least 300 to 500 individuals should be included. Moreover, the reference population should be selected on the basis of a health questionnaire, screening for renal function and ventricular dysfunction. In this study, we selected 1485 young and elderly adults from the population seeking a routine health check-up who met the criteria of international guidelines.

Several limitations of this study should be mentioned. First, individuals with subclinical coronary heart disease could not be excluded based on the electrocardiogram and echocardiography. In addition, natriuretic peptides as a surrogate marker for underlying myocardial dysfunction were not investigated in this study. Second, the relatively small sample size in the aged 66 years or older category could not satisfy the recommended minimum
number of 300 participants for subgroup analysis,[23] making it unreliable to examine the effect of age on the hs-cTnI concentration. Finally, this study was purely an analytical evaluation of the hs-cTnI assay. Therefore, diagnostic performance of the Abbott hs-cTnI assay needs to be further investigated.

5. Conclusions
Using the Abbott hs-cTnI assay, we established 28.0 pg/mL as the 99th percentile value for hs-cTnI in healthy adults from the Sichuan area; this value was close to the manufacturer’s recommendation. Men had a higher 99th percentile hs-cTnI value than women at ages 18 to 65 years. The current study supports the notion that individual laboratories need to establish their own age- and gender-specific threshold values for hs-cTnI when defining reference intervals. Establishing a reference interval for hs-cTnI that is suitable for the healthy Chinese population may improve medical decision-making.

References
[1] Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173–95.
[2] Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356–75.
[3] Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020–35.
[4] Jarolim P. High sensitivity cardiac troponin assays in the clinical laboratories. Clin Chem Lab Med 2015;53:63–52.
[5] Venge P, Johnston N, Lindahl B, et al. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009;54:1163–72.
[6] Sandoval Y, Smith SW, Apple FS. Present and future of cardiac troponin in clinical practice: a paradigm shift to high-sensitivity assays. Am J Med 2016;129:354–65.
[7] Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54–61.
[8] Collinson PO, Heung YM, Gaze D, et al. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012;58:219–25.
[9] Aw TC, Phua SK, Tan SP. Measurement of cardiac troponin I in serum with a new high-sensitivity assay in a large multi-ethnic Asian cohort and the impact of gender. Clin Chim Acta 2013;422:26–9.
[10] Krintus M, Kozinski M, Boudry P, et al. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clin Chem Lab Med 2014;52:1657–65.
[11] Zeller T, Ojeda F, Brunner FJ, et al. High-sensitivity cardiac troponin I in the general population – defining reference populations for the determination of the 99th percentile in the Gutenberg Health Study. Clin Chem Lab Med 2015;53:699–706.
[12] Choo V, WHO reasseses appropriate body-mass index for Asian populations. Lancet 2002;360:235.
[13] Horwitz S, Altai. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline, Third Edition, 2008; CLSI C28-A3E.
[14] Ji M, Moon HW, Hur M, et al. Determination of high-sensitivity cardiac troponin I 99th percentile upper reference limits in a healthy Korean population. Clin Biochem 2016;49:736–61.
[15] Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574–81.
[16] Krintus M, Kozinski M, Boudry P, et al. Defining normality in a European multinational cohort: critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. Int J Cardiol 2015;187:256–63.
[17] Zhang CY, Song LY, Wu J, et al. The analytical performance assessment and clinical practice of three sensitive cardiac troponin I assays. Chin J Lab Med 2010;33:819–24.
[18] Vaskaran SD, Macdonald SP, Sikaris KA. High-sensitivity cardiac troponin assays for risk stratification and for the diagnosis of acute myocardial infarction. Ann Clin Biochem 2012;49:209–10.
[19] Franzini M, Lorenzoni V, Masiotti S, et al. The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: a multicenter study in Italy. Clin Chim Acta 2015;438:376–81.
[20] Eggers KM, Lind I, Venge P, et al. Factors influencing the 99th percentile of cardiac troponin I evaluated in community-dwelling individuals at 70 and 75 years of age. Clin Chem 2013;59:1068–73.
[21] Schamhorst V, Krasznai K, van ’t Veer M, et al. Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain. Clin Chem 2012;58:1208–14.
[22] Hickman PE, Badrick T, Wilson SR, et al. Reporting of cardiac troponin – problems with the 99th population percentile. Clin Chim Acta 2007;381:182–3.
[23] Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010;31:2197–204.